61 /100
HIGH RISK
Score updated Jul 14, 2026

PTHS — Pelthos Therapeutics Inc. Dilution Risk Tracker

Track PTHS dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track PTHS — Get alerts when the score changes →

As of July 14, 2026, Pelthos Therapeutics Inc. (PTHS) has a DilutionWatch DilutionScore of 61/100, rated HIGH dilution risk. Pelthos Therapeutics Inc. has a market capitalization of $92.00M, 3.48M shares outstanding, 17 institutional holders tracked. Key dilution vectors include approximately 24 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
80
💰 Cash Runway
10
📊 Float Risk
52
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
23%
🔁 Convertible Conversion 40%
• Significant convertible debt: 19% potential dilution
• Elevated convertible risk (60/100)
📉 Score Deterioration 10%
• Score in HIGH risk zone (61/100)
🔔 Track PTHS — Get forecast alerts →

💹 Market Data

Market Cap$92.00M
Shares Outstanding3.48M
Float1.47M
Cash$31.98M
Debt$52.93M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 11.5% shares (2026Q1 vs prior)
17 institutional holders · 1.01M shares
#1 Murchinson Ltd. 296.3K shares
#2 Ikarian Capital, LLC 256.6K shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 186.2K shares
+ 14 more holders Sign up free to view →

📉 Short Interest

Short Interest27.8K
Days to Cover1.0
% of Float1.9%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Mar 31, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2025
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for PTHS Shareholders

Pelthos Therapeutics Inc. (PTHS) has a DilutionScore of 61/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

DilutionWatch's EDGAR monitoring for PTHS shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for PTHS in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for PTHS alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track PTHS Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking PTHS — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for PTHS
📊 PTHS FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 PTHS Signal Convergence & Dark Pool Activity — StonkWhisper 📄 PTHS Dilution Risk Analysis — Full In-Depth Report

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.